Overview

Bioequivalence of Bicalutamide New Formulation in Japan

Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the bioequivalence of Bicalutamide new formation with Casodex commercial tablet (80mg) in Japanese healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Bicalutamide